Navigation Links
Houlihan Smith to Host Illinois Venture Capital Association Luncheon Seminar on Midwest Healthcare Investing
Date:4/3/2009

CHICAGO, April 3 /PRNewswire/ -- Houlihan Smith & Company, Inc. will host an upcoming Illinois Venture Capital Association luncheon seminar on "Healthcare Investing: Midwest Home-Grown Successes." The event will be held at the UBS Tower, One North Wacker Drive in Chicago, at 11:30 a.m. Wednesday, April 22.

Reginald McGaugh, Managing Director, will moderate the event, which will feature a panel discussion with executives from some of the most successful companies in the Midwest healthcare sector. Topics will include recent M&A activity and the paradigm shift in the healthcare market, along with emerging trends, Midwest success stories, and what lies ahead.

The discussion will include a presentation by Smart Medical Technology, Inc., (SMT) whose featured product is the patented and FDA-approved Liftaem(TM) lateral patient transfer system. Based in Darien, Illinois, SMT has developed a convenient transfer mat that is placed on a hospital bed or gurney and inflated with a portable air compressor. The system allows one nurse or clinician, instead of a team of six to eight people, to safely transfer elderly, obese, injured, or critically ill patients at a hospital, surgery center, skilled nursing home, assisted living center, and any other acute care setting.

McGaugh heads the Global Healthcare Markets Group at Houlihan Smith. He has extensive experience and relationships in the healthcare sector, including biotechnology firms, medical device manufacturers, providers, and managed care companies. McGaugh's experience also includes the energy, telecommunications, and transportation sectors. Along with his focus and expertise on healthcare, he also directs clients on the advisory side of deals structured in compliance with Islamic Law (Shariah Compliant) as Houlihan Smith expands into Africa and the Middle East.

Houlihan Smith & Company, Inc. is a
'/>"/>

SOURCE Houlihan Smith & Company, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Houlihan Smith Arranges Equity Investment Into Tri-Tech Health, LLC
2. GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder
3. United States Patent & Trademark Office (USPTO) Rules in Smith & Nephews Favor and Confirms Patent Claims Infringed by Arthrex Inc.
4. Blue Cross and Blue Shield of Illinois Teams with Chicago Bears Coach Lovie Smith in Diabetes Awareness Drive
5. Smith & Nephew Announces Symposium for Optimizing Outcomes in Burn Care
6. IADR and GlaxoSmithKline Consumer Healthcare announce winners of 2009 Innovation in Oral Care Awards
7. Smithsonian Worker Exposed to Asbestos Files Whistleblower Retaliation Complaint
8. GlaxoSmithKline Consumer Healthcare to Reach 85 Percent of the Worlds Smokers with Quit Aids
9. GlaxoSmithKline Consumer Healthcare Helps to Bridge Oral Care Gap in Appalachia
10. Smith & Nephew Introduces RENASYS(TM) GO, Portable NPWT for Mobile, Active Patients
11. Photos: The American Diabetes Association, Fitness Expert Kathy Smith and Beachbody(R) Join Forces to Combat Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2013)... June 20, 2013 This ... focuses mainly on the oral and injectable ... report enumerates the various formulation technologies involved ... and advantages of specific technologies. Wherever possible, ... been discussed as proof of validation along ...
(Date:6/20/2013)... Beverly Hills, CA (PRWEB) June 20, 2013 ... David M. Amron, has been named by The Patient’s ... as an expert in liposuction, Dr. Amron will now ... Patient’s Guide. The Patient's Guide sees over one million ... provides information and articles related to plastic surgery and ...
(Date:6/20/2013)... Novatus Contract Management , the ... next release of upgrades and enhancements will be available ... system more robust, but continue to add investment value ... Online Negotiation Portal™ Interface enhancements – ... Portal from the outside. , Company Relationships ...
(Date:6/20/2013)... 20, 2013 Presenting at the ... society president and keynote speaker Dr. Rod ... future of rhinoplasty (plastic surgery of the nose) ... from across the nation. In his address, Dr. ... rhinoplasty to current open-technique rhinoplasty that reduces risk ...
(Date:6/20/2013)... weight may not reverse the damage that has been done ... even moderate weight loss can have a dramatic effect on ... within normal and healthy weight ranges is ideal, starting with ... shown to help relieve joint pain, as well as help ... have revealed that a weight loss of 11 pounds decreases ...
Breaking Medicine News(10 mins):Health News:Novel Drug Delivery Systems Market (NDDS): Formulations (Oral & Injectable) Analysis in Research Report at RnRMarketResearch.com 2Health News:Novel Drug Delivery Systems Market (NDDS): Formulations (Oral & Injectable) Analysis in Research Report at RnRMarketResearch.com 3Health News:Novel Drug Delivery Systems Market (NDDS): Formulations (Oral & Injectable) Analysis in Research Report at RnRMarketResearch.com 4Health News:Liposuction Guru, Dr. David Amron, Receives Award From The Patient’s Guide 2Health News:Novatus Contract Management Newest Enhancements and Upgrades to be Available July 1 2Health News:Dr. Rod J. Rohrich Delivers Keynote Address on the Future of Rhinoplasty 2Health News:Dr. Rod J. Rohrich Delivers Keynote Address on the Future of Rhinoplasty 3Health News:Dr. Rod J. Rohrich Delivers Keynote Address on the Future of Rhinoplasty 4Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Diet Plans, Now Capable of Helping Patient’s Avoid The Risk of Arthritis With Natural Weight Loss 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Diet Plans, Now Capable of Helping Patient’s Avoid The Risk of Arthritis With Natural Weight Loss 3
... SPRING, Md., Feb. 28 Celebrity chef Emeril,Lagasse joins ... top,quality food with viewers this summer in the new ... 24/7 eco-lifestyle,television network, is set to launch in June ... premiering throughout the summer, including,EMERIL GREEN (wt) which will ...
... TDP-43 mutations expose potential therapeutic target, experts say , , ... a new, yet rare, genetic mutation in the development ... only exposes a potential therapeutic target for treating the ... mutation sets in motion the mechanism that causes many ...
... and men are completely satisfied with the time they spend ... study published in the Journal of Family Issues. , ... be more time pressured than those who work part time ... professor of sociology at Kent State University. , In ...
... will Integrate IDC,s X1590 into the First Standardized ... ... /PRNewswire-FirstCall/ - IDC (Imaging Dynamics Company,Ltd.) (TSX: IDL), the global ... announced that Halifax Biomedical has selected,IDC,s X1590 as the DR ...
... PRINCETON, N.J., Feb. 28 Organizations,representing the state,s ... funding cuts proposed for hospital care for New ... $33 billion state spending plan for 2009, released,Tuesday, ... with funding of $608,million compared with current funding ...
... unlocked some of the mysteries of how the developing ... A present in the maternal blood stream. Their results ... Journal of Biological Chemistry. , The researchers studied ... formation of vitamin A stores in the body, during ...
Cached Medicine News:Health News:Emeril Lagasse and Planet Green Partner with Whole Foods Market(R) on Innovative New Series 2Health News:Emeril Lagasse and Planet Green Partner with Whole Foods Market(R) on Innovative New Series 3Health News:New Gene for Lou Gehrig's Disease Identified 2Health News:New Gene for Lou Gehrig's Disease Identified 3Health News:IDC X-Series DR system selected for use in leading edge RSA clinical trial application 2Health News:IDC X-Series DR system selected for use in leading edge RSA clinical trial application 3Health News:Hospital Groups United in Opposition to Charity Care Cuts 2Health News:Rutgers researchers unlock mysteries of vitamin A metabolism during embryonic development 2Health News:Rutgers researchers unlock mysteries of vitamin A metabolism during embryonic development 3
(Date:6/19/2013)... -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC ... of Medicine ( NEJM ) published results online ... Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib in patients with ... (SLL). Ibrutinib was shown to be safe and effective ... patients who were at high-risk due to factors such ...
(Date:6/19/2013)... 2013 A decade-long JDRF-funded study led by ... Germany , is providing a deeper ... of developing type 1 diabetes (T1D), highlighting the importance ... The study, "Seroconversion to Multiple Islet Autoantibodies and Risk ... in The Journal of the American Medical Association ...
(Date:6/19/2013)... June 19, 2013  Finesse Solutions, Inc, a ... sciences process applications, announced the launch of its ... cell culture and fermentation.  The 3L glass vessels ... of Finesse bioreactors and are designed to optimize ... are fully compatible with all Finesse G3Lab controllers, ...
Breaking Medicine Technology:Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 2Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 4Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 5Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 6New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 2New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 3Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2
... Inc.,(Nasdaq: NVAX ) today announced that the Company ... the Phase I/IIa human clinical,trial of Novavax,s H5N1 pandemic ... August 26, 2008., The call will be hosted ... and other members of senior management, including,Chief Medical Officer, ...
... Johnson & Johnson Pharmaceutical,Research & Development, ... Food,and Drug Administration (FDA) requires additional information ... Application (NDA) for DORIBAX(TM),(doripenem for injection) for ... nosocomial pneumonia (NP), including ventilator-associated,pneumonia (VAP)., ...
Cached Medicine Technology:Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008 2FDA Requires Additional Information on DORIBAX for Treatment of Hospital-Acquired Pneumonia 2FDA Requires Additional Information on DORIBAX for Treatment of Hospital-Acquired Pneumonia 3FDA Requires Additional Information on DORIBAX for Treatment of Hospital-Acquired Pneumonia 4FDA Requires Additional Information on DORIBAX for Treatment of Hospital-Acquired Pneumonia 5